A Longitudinal Cohort Study to Quantify Rectal and Seminal HIV-1 RNA Decay in Antiretroviral Therapy (ART)-Naive HIV-Infected Men who have Sex with Men(MSM) Initiating DTG/ABC/3TC Regimen
Latest Information Update: 29 Nov 2019
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
Most Recent Events
- 26 Nov 2019 Results assessing time to viral suppresssion in rectal and seminal reservoirs in treatment-naive MSM starting ART with the fixed-dose combination dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) published in the Journal of Antimicrobial Chemotherapy
- 07 May 2019 New trial record